Hepatitis C virus in human immunodeficiency virus-infected individuals: An emerging comorbidity with significant implications

Seminars in Liver Disease

Volumn 23, Issue 2, 2003, Pages 149-166

  Gonzalez, Stevan A ^a   Talal, Andrew H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coinfection; Hepatitis C virus; Human immunodeficiency virus

Indexed keywords

ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CILUPREVIR; CORTICOSTEROID; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MUSCARINIC AGENT; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; THYROID HORMONE; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BIRTH DEFECT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; FATIGUE; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LUNG INFILTRATE; MENTAL DISEASE; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; OPTIC NERVE DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSORIASIS; RETINA HEMORRHAGE; SCREENING TEST; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; THYROID DISEASE; VIROLOGY; VOMITING;

HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 0038282724     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39946     Document Type: Article

References (149)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;351:556-562
2. Centers for Disease Control and Prevention, Office of Communication. Facts about hepatitis C [on-line]. Available: www.cdc.gov/od/oc/media/fact/hepcqa.htm; October 1998; accessed November 29, 2002
3. Centers for Disease Control and Prevention. HIV/AIDS update: a glance at the HIV epidemic [on-line]. Available: www.cdc.gov/hiv/pubsd/facts.htm; accessed November 29, 2002
4. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30:S77-84
5. Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis 1999;29: 150-154
6. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338: 853-860
7. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497
8. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-1023
9. Serfaty L, Costagliola D, Wendum D, et al. Impact of earlyuntreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. AIDS 2001;15:2011-2016
10. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-137
11. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-19
12. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. Hepatology 1999;30:1054-1058
13. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection. Lancet 2000;356:1800-1805
14. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:2125-2132
15. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206
16. Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? JAMA 2002;288:241-243
17. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80
18. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-1263
19. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-co-infected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-287
20. Memon MI, Memon MA. Hepatitis C: an epidemiological review. J Viral Hepat 2002;9:84-100
21. World Health Organization. Hepatitis C. Fact Sheet No. 164 [on-line]. Revised October 2000. Available: www.who.int/inffs/en/fact164.html; accessed November 25, 2002
22. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79:515-536
23. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996; 125:634-639
24. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-758
25. Nousbaum J, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122:161-168
26. Zein NN, Poterucha JJ, Gross JB, et al. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 1996;91:2560-2562
27. Serfaty L, Chazouilleres O, Poujol-Robert A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997; 26:776-779
28. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832
29. Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001;39:119-124
30. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-842
31. World Health Organization. Report on the global HIV/AIDS epidemic 2002 [on-line]. Available: www.who.int/hiv/pub/epidemiology/pubepidemic2002/en/; accessed November 29, 2002
32. Quiñones-Mateu ME, Gao Y, Ball SC, et al. In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms. J Virol 2002;76:9600-9613
33. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002;83:1253-1265
34. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;36:737-742
35. Centers for Disease Control, National Center for Infectious Diseases. Viral hepatitis C fact sheet [on-line]. Available: www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm; accessed on November 29, 2002
36. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs co-infected with HIV. Am J Gastroenterol 1996;91:2563-2568
37. Pol S, Vallet-Pichard A, Fontaine H, Lebray P. HCV infection and hemodialysis. Semin Nephrol 2002;22:331-339
38. Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. J Infect Dis 2000;181:1475-1478
39. Eyster MC, Alter HJ, Aledort LM, et al. Heterosexual cotransmission of hepatitis C virus and human immunodeficiency virus. Ann Intern Med 1991;115:764-768
40. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency infection in the index case: A Multicentre Study of 423 Pairings. J Intern Med 1994;236:515-519
41. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-229
42. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J Infect Dis 1998;177:1480-1488
43. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929
44. Patchen L, Khoshnood K. Risk of perinatal transmission with treatment combinations of intrapartum and newborn zidovudine monotherapy. AIDS Read 2001;11:269-277
45. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999;354:795-802
46. Hiratsuka M, Minakami H, Koshizuka S, Sato I. Administration of interferon-α during pregnancy: effect on fetus. J Perinat Med 2000;28:372-376
47. Koretz RL, Brezina M, Polito AJ, et al. Non-A, non-B post-transfusion hepatitis: comparing C and non-C hepatitis. Hepatology 1993;17:361-365
48. Thimme R, Oldach D, Chang K, et al. determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406
49. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-264
50. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis: A National Heart, Lung, and Blood Institute Collaborative Study. Hepatology 2001;33:455-463
51. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233
52. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) singlesource outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-96
53. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic liver disease. MMWR Morb Mortal Wkly Rep 1998;47:1-39
54. Mehta S, Levey JM, Bonkovsky HL. Extrahepatic manifestations of infection with hepatitis C virus. Clin Liver Dis 2001;5:979-1008
55. Pugh RNH, Murray-Lyon IM, Dawson JL, Peitroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-648
56. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871
57. Brown RS, Kumar KS, Russo MW, et al. Model for endstage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing Status 2A Patients. Liver Transplant 2002;8:278-284
58. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470
59. Pagliaro L. MELD: the end of Child-Pugh classification? J Hepatol 2002;36:141-142
60. Kato Y, Nakata K, Omagari K, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994;74:2234-2238
61. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:34S-38S
62. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocelluar carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131:174-181
63. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35:S72-S78
64. Ishikawa T, Ichida T, Yamagiwa S, et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001;16:1274-1281
65. Roudot-Thoraval F, Bastie A, Pawlotsky J, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997;26:485-490
66. Bruno R, Sacchi P, Filice C, Puoti M, Filice G. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. J Acquit Immune Defic Syndr 2002; 30:535-536
67. Izumi N, Asahina Y, Noguchi O, et al. Risk factors for distant recurrence of hepatocellular caricinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001;91:949-956
68. Hanazaki K, Wakabayashi M, Sodeyama H, et al. Surgical outcome in cirrhotic patients with hepatitis C-related hepatocellular carcinoma. Hepatogastroenterology 2000;47:204-210
69. Weber J. The pathogenesis of HIV-1 infection. Br Med Bull 2001;58:61-72
70. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-165
71. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-1107
72. Moylett EH, Shearer WT. HIV: clinical manifestations. J Allergy Clin Immunol 2002;110:3-16
73. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994;87:555-561
74. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002;99: 15661-15668
75. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999;354:1782-1785
76. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-107
77. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35
78. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med 1999;190:841-850
79. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126
80. Appay V, Papagno L, Spina C, et al. Dynamics of T cell responses in HIV infection. J Immunol 2002;168:3660-3666
81. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122
82. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Early HCV viral dynamics in HIV/HCV-infected patients on HCV treatment. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002; Seattle, WA. Abstract 121
83. Sherman KE, Horn P, Rouster S, et al. HCV RNA kinetic response to PEG-interferon and ribavirin in HIV co-infected patients. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections. February 24, 2002; Seattle, WA. Abstract 122
84. Talal AH, Shata MT, Flynn SM, et al. HCV dynamics in HIV/HCV co-infected patients treated with pegylated interferon and ribavirin. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 154
85. Talal AH, Flynn SM, Dorante G, et al. Hepatitis C virus dynamics HIV/HCV co-infection in response to daily, high-dose interferon-α-2a. Presented at the 52nd Annual Meeting of AASLD. November 9-13, 2001; Dallas, TX. Abstract 1529
86. Mehal WZ, Azzaroll F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001;120:250-260
87. Bertolino P, Trescol-Biemont MC, Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 1998;28:221-236
88. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001;21:417-426
89. Nuovo GJ, Holly A, Wakely P, Frankel W. Correlation of histology, viral load, and in situ viral detection in hepatic biopsies from patients with liver transplants secondary to hepatitis C infection. Hum Pathol 2002;33:277-284
90. Garson JA, Tuke PW, Makris M, et al. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet 1990; 336:1022-1025
91. Tremolada F, Casarin C, Tagger A, et al. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med 1991;114:277-281
92. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346-355
93. Grüner NH, Gerlach TJ, Jung M, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-1536
94. Brown PMJ, Neuman MG. Immunopathogenesis of hepatitis C viral infection: TH1/TH2 responses and the role of cytokines. Clin Biochem 2001;34:167-171
95. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1999;383:787-793
96. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001;21:427-435
97. Canchis PW, Davila J, Fiel MI, et al. Characterization of intrahepatic lymphocytes and hepatocytes in HIV/HCV coinfected and HCV mono-infected individuals. Presented at the Ninth International Meeting on Hepatitis C Virus and Related Viruses. July 7-11, 2002; San Diego, CA
98. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 2001;82:1807-1814
99. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-960
100. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170
101. Mohri H, Perelson AS, Tung K, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by anti-retroviral therapy. J Exp Med 2001;194:1277-1287
102. Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000;96:2 951-2964
103. McHutchison JG, Shad JA, Gordon SC, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001;8:414-420
104. Housset C, Lamas E, Courgnaud V, et al. Presence of HIV-1 in human parenchymal and non-parenchymal liver cells in vivo. J Hepatol 1993;19:252-258
105. Cao YZ, Dieterich D, Thomas PA, et al. Identification and quantitation of HIV-1 in the liver of patients with AIDS. AIDS 1992;6:65-70
106. Hufert FT, Schmitz J, Schreiber M, et al. Human Kupffer cells infected with HIV-1 in vivo. J Acquir Immune Defic Syndr 1993;6:772-777
107. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV infected persons. MMWR Morb Mortal Wkly Rep 2002;51:1-46
108. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456
109. Talal AH. Hepatitis C virus in people with HIV infection. Lancet 2002;360:2088-2089
110. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 [on-line]. June 10-12, 2002, revisions September 12, 2002;19:1. Available: consensus.nih.gov/cons/116/091202116cdc statement.htm; accessed November 29, 2002
111. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-582
112. Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000;38:575-577
113. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-293
114. The METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20
115. McHutchison JG, Davis GL, Esteban-Mur R, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon α-2b alone or in combination with ribavirin. Presented at the 52nd Annual Meeting of AASLD. November 9-13, 2001; Dallas, TX. Abstract 281
116. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
117. Fried MW, Shiffman ML, Reddy KR, et al. Pegterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
118. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457
119. Bini EJ, Reid M, Mannix RA, Wu B. Safety and efficacy of interferon alfa-2b and ribavirin combination therapy for the treatment of hepatitis C in patients coinfected with HIV. Presented at the 52nd Annual Meeting of AASLD. November 9-13, 2001; Dallas, TX. Abstract 653
120. Puoti M, Barbara Z, Paolo Q, et al. Human immune deficiency virus (HIV) co-infection impairs responsiveness to interferon (IFN) and ribavirin (RBV) combination in patients with chronic hepatitis C: preliminary results of a comparative study. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 506
121. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV co-infected subjects: an early report. Gut 2000; 47:694-697
122. Nasti G, Di Gennaro G, Tavio M, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alpha-2b and ribavirin. AIDS 2001;15: 1783-1787
123. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-a2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149-2155
124. Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34:1035-1040
125. Kostman JR, Smith JJ, Giffen CA, Frost KR. Interferon α2b/ribavirin combination therapy in HIV/HCV co-infected persons: results of a multicenter randomized, double-blind, controlled trial (American Foundation for AIDS Research Study). Presented at the 52nd Annual Meeting of AASLD. November 9-13, 2001; Dallas, TX. Abstract 634
126. Khalili M, Hoffman-Terry M, Hassahein TI, et al. Safety and efficacy of 40 kDa peginterferon alfa-2a (Pegasys) in the treatment of patients co-infected with HIV and HCV: preliminary results from a randomized, multicenter trial. Presented at the 52nd Annual Meeting of AASLD. November 9-13, 2001; Dallas, TX. Abstract 623
127. Hopkins S, Hennessy M, Lyons F, Mulachy F, Bergin C. Treatment of chronic hepatitis c with pegylated interferon and ribavirin in HIV co-infected patients. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 258
128. Myers RP, Benhamou Y, Bochet M, et al. Pegylated interferon alfa-2b and ribavirin in HIV/HCV-coinfected patients. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 1649
129. Perronne C, Carrat F, Banisadr F, et al. ANRS HC02RIBAVIC: a randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs. interferon alpha-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV Co-Infected Patients. Presented at the 42nd ICAAC. September 27-30, 2002; San Diego, CA. Abstract H-1083
130. Chung R, Anderson J, Alston B, et al. A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection. ACTG A5071. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections. February 24, 2002; Seattle, WA. Abstract LB-15
131. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001;33:419-423
132. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231
133. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-936
134. Bekkering FC, Brouwer JT, Schalm SW, Elewaut A. Hepatitis C: viral kinetics. Hepatology 1997;26:1691-1693
135. Pesce A, Taillan B, Rosenthal E, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993;341:1597
136. Talal AH. Opportunistic infections in HIV-infected individuals: hepatitis C virus. Lancet 2002;360:584-586
137. Fontaine H, Pol S. Side effects of interferon-α in treating hepatitis C virus infection. Transplant Proc 2001;33:2327-2329
138. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185:S128-S137
139. Hinrichsen et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 866
140. Benhamou Y, Hinrichsen H, Sentjens R, et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 563
141. Soler M, McHutchison JG, Kwoh J, et al. Treatment of chronic hepatitis C with ISIS 14803, an antisense oligonucleotide inhibitor of HCV. Effect of target region sequence on antiviral efficacy. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 469
142. Davis GL, Balan V, Sulkowski MS, et al. A phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of escalating doses of a novel recombinant human albumin-interferon fusion protein (albuferon) in subjects with chronic hepatitis C. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 490
143. Eren R, Ilan E, Nussbaum O, et al. Development and clinical evaluation of human monoclonal antibodies for treating HCV infection. Presented at the 53rd Annual Meeting of AASLD. November 2-5, 2002; Boston, MA. Abstract 498
144. Yenni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002;288:222-235
145. The Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [on-line]. February 4, 2002. Available: aidsinfo.nih.gov/guidelines/default_dbz.asp?id=50; accessed December 7, 2002
146. Torre D, Tambini R, Cadario F, et al. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001;33:1579-1585
147. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-1327
148. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. Morb Mortal Wkly Rep 2001;49:1153-1156
149. Randall G, Rice CM. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies. Curr Opin Infect Dis 2001;14:743-747